Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 126
3 154
2 49
1 24
NEB 5
Curative setting
A 53
C 2
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 35
Endocrine Tumours 21
Gastrointestinal Cancers 69
Genitourinary Cancers 70
Gynaecological Malignancies 39
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Sarcoma 11
Skin Cancers 29
TMB-H solid tumours 1
Thoracic Malignancies 82
Tumor agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 2
Skin Cancers 14
TMB-H solid tumours 0
Thoracic Malignancies 10
Tumor agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Apalutamide ADT (androgen deprivation therapy) ADT + placebo In adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). TITAN
    Genitourinary Cancers
    		 Prostate cancer - TITAN

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pasireotide - Single arm Advanced carcinoids of the lung and thymus LUNA
    Endocrine Tumours
    		 Neuroendocrine Tumour - Lung and thymic carcinoids - LUNA

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F3
      3
    Everolimus - Single arm Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease LUNA
    Endocrine Tumours
    		 Neuroendocrine Tumour - Lung and thymic carcinoids - LUNA

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F3
      3
    Everolimus Pasireotide Single arm Advanced carcinoids of the lung and thymus LUNA
    Endocrine Tumours
    		 Neuroendocrine Tumour - Lung and thymic carcinoids - LUNA

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F3
      2
    Cetuximab Cisplatin or carboplatin plus 5-FU Cisplatin or carboplatin plus 5-FU Treatment of patients with squamous cell cancer of the head and neck in combination with platinum-based chemotherapy for recurrent and/or metastatic disease EXTREME
    Head and neck cancer
    		 Squamous cell - EXTREME

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Nivolumab - Investigator choice (methotrexate or cetuximab or docetaxel) As monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy CheckMate141
    Head and neck cancer
    		 Squamous cell - CheckMate141

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Rucaparib - Single arm (Phase II) Platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. ARIEL2
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer BRCA mutation ARIEL2

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Rucaparib - Placebo Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy ARIEL3
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer Homologous recombination deficiencies (HRD) (BRCA mutant or BRCA wild-type and high loss of heterozygosity) ARIEL3

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Rucaparib - Placebo Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy ARIEL3
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer Germline or somatic - BRCA mutation ARIEL3

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Rucaparib - Placebo Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy ARIEL3
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer - ARIEL3

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Atezolizumab Carboplatin and etoposide Placebo plus carboplatin and etoposide First-line treatment of extensive-stage SCLC IMpower133
    Thoracic Malignancies
    		 Small-cell Lung Cancer - IMpower133

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Pembrolizumab - Cisplatin or carboplatin/5-FU/cetuximab As monotherapy is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1 KEYNOTE-048
    Head and neck cancer
    		 Squamous cell CPS PD-L1 expression ≥1 KEYNOTE-048

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pembrolizumab - Cisplatin or carboplatin/5-FU/cetuximab As monotherapy is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1 KEYNOTE-048
    Head and neck cancer
    		 Squamous cell CPS PD-L1 expression ≥20 KEYNOTE-048

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pembrolizumab Cisplatin or carboplatin/5-FU Cisplatin or carboplatin/5-FU/cetuximab In combination with platinum and 5‑fluorouracil (5‑FU) chemotherapy is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1 KEYNOTE-048
    Head and neck cancer
    		 Squamous cell CPS PD-L1 expression ≥1 KEYNOTE-048

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pembrolizumab - Standard of care (methotrexate, docetaxel or cetuximab) Recurrent or metastatic SCCHN in adults whose tumours express PD-L1 with a ≥50% TPS and progressing on or after platinum-containing ChT KEYNOTE-040
    Head and neck cancer
    		 Squamous cell CPS PD-L1 expression ≥1 KEYNOTE-040

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Sunitinib - Placebo Advanced GIST 2nd line after imatinib
    Sarcoma
    		 GIST - -

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Regorafenib Best supportive care Placebo plus best supportive care Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib. GRID
    Sarcoma
    		 GIST - GRID

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Pazopanib - Placebo Previously treated non-GIST metastatic soft tissue sarcoma PALETTE
    Sarcoma
    		 Soft tissue - PALETTE

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Eribulin - Dacarbazine Unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease
    Sarcoma
    		 Soft tissue - Liposarcoma or leiomyosarcoma - -

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Imatinib 1-year - Placebo Adjuvant for GIST patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry ACOSOG Z9001
    Sarcoma
    		 GIST KIT+ ACOSOG Z9001

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Imatinib 3-years - Imatinib 1-year Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment. SSG XVIII
    Sarcoma
    		 GIST KIT+ SSG XVIII

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Olaparib - Placebo Maintenance treatment of adult patients with gBRCAm who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line ChT regimen POLO
    Gastrointestinal Cancers
    		 Pancreatic cancer gBRCAm POLO

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Entrectinib - Single arm trials (Phase I/II) Treatment of adult and paediatric patients older than 1 month with solid tumours that have NTRK gene fusion, who have disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options. STARTRK-1; STARTRK-2; ALKA-372-001
    Tumour agnostic
    		 - NTRK gene fusion STARTRK-1; STARTRK-2; ALKA-372-001

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Entrectinib - Single arm Treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors STARTRK-1; STARTRK-2; ALKA-372-001
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer Refractory NTRK fusion–positive cancers STARTRK-1; STARTRK-2; ALKA-372-001

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Avapritinib - Single arm Treatment of adult patients with unresectable or metastatic GIST harbouring the platelet-derived growth factor receptor alpha D842V mutation NAVIGATOR
    Sarcoma
    		 GIST PDGFRA D842V-mutant NAVIGATOR

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Durvalumab Etoposide and either carboplatin or cisplatin Platinum-etoposide First-line treatment of extensive-stage SCLC CASPIAN
    Thoracic Malignancies
    		 Small-cell Lung Cancer - CASPIAN

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Brigatinib - Crizotinib Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor ALTA-1L
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ ALTA-1L

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Niraparib - Placebo Maintenance treatment for advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy PRIMA/ENGOT-OV26/COG-3012
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer - PRIMA/ENGOT-OV26/COG-3012

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Atezolizumab Bevacizumab Sorafenib Advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy IMbrave150
    Gastrointestinal Cancers
    		 Hepatobiliary Cancers - Hepatocellular Carcinoma - IMbrave150

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Olaparib - Enzalutamide or abiraterone (crossover allowed) Treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent PROfound
    Genitourinary Cancers
    		 Prostate cancer Patients with ≥1 alteration in BRCA1, BRCA2 or ATM PROfound

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.